International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) - Part I: Upper facial wrinkles

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 11, 2010, Pages 1278-1284

  Ascher, B ^a   Talarico, S ^b   Cassuto, D ^c   Escobar, S ^d   Hexsel, D ^e   Jaen P ^f   Monheit, G D ^g   Rzany, B ^h   Viel, M ⁱ  

^a Clinique de Chirurgie Esthetique Iena   (France)

^b Universidade Federal de San Paulo   (Brazil)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g TOTAL   (France)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ London Centre for Aesthetic Surgery   (United Kingdom)

Author keywords

Botulinum toxin type A; Consensus; Facial wrinkle; Speywood

Indexed keywords

AZZALURE; BOTULINUM TOXIN A; UNCLASSIFIED DRUG;

ANATOMY; ARTICLE; CONSENSUS DEVELOPMENT; DRUG SAFETY; EYEBROW; FACE; FOREHEAD; HEADACHE; HEMATOMA; HUMAN; INJECTION SITE; INJECTION SITE REACTION; ORBICULARIS OCULI MUSCLE; PRIORITY JOURNAL; PTOSIS; TREATMENT OUTCOME; WRINKLE;

BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; FOREHEAD; HUMANS; INTERNATIONAL COOPERATION; NEUROTOXINS; PRACTICE GUIDELINES AS TOPIC; SKIN AGING;

EID: 78649733007     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03631.x     Document Type: Article

References (34)

1. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000; 43: 249-259.
2. Sadick NS. The impact of cosmetic interventions on quality of life. Dermatol Online J 2008; 14: 2.
3. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994; 344: 474-475.
4. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2008; 34: 1-8.
5. Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Carid D. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4103 treatments in 945 patients. Dermatol Surg 2007; 33: S18-S25.
6. Markey AC. Dysport. Dermatol Clin 2004; 22: 213-219.
7. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995; 18: 720-729.
8. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: A report of 175 cases. J Neurol Neurosurg Psychiatry 1998; 64: 751-757.
9. de Maio M, Rzany B. Botulinum Toxin in Aesthetic Medicine. Springer, Heidelberg, 2007.
10. Ascher B, Landau M, Rossi B. Injection treatments in cosmetic surgery. Informa Healthcare, London. Editor 2008
11. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin A in female patients with upper facial rhytides: Safety and efficacy. J Am Acad Dermatol 2009; 60: 972-979.
12. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-262.
13. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: Double-blind, placebocontrolled, dose-ranging study. Dermatol Surg 2009; 35: 1478-1486.
14. Flynn TC, Carruthers JA, Carruthers JA, Clark RE II. Botulinum A toxin (BOTOX) in the lower eyelid:dose-finding study. Dermatol Surg 2003; 29: 943-950.
15. Rzany B, Fratila A, Heckmann M. Expertentrffen zur Anwendung von Botulinumtoxin A in der Ästhetischen Dermatologie. Kosmetische Medizin 2005; 3: 1-8.
16. Sommer B, Bergfeld D, Sattler G. Consensus recommendations on the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol Ges 2007; 5(Suppl. 1): S1-S29.
17. Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 114(Suppl. 1): S1-S22.
18. Carruthers J, Glogau RG, Blitzer A. Advances in facial rejuvenation: Botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies - consensus recommendations. Plast Reconstr Surg 2008; 121: S5-S30.
19. Lewis CM, Lavell S, Simpson MF. Patient selection and patient satisfaction. Clin Plast Surg 1983; 10: 321-332.
20. Ascher B, Zakine B, Kestemont P et al. Botulinum toxin A in the treatment of glabellar lines: Scheduling the next injection. Aesthet Surg J 2005; 25: 365-375.
21. Rzany B, Ascher B, Fratila A, Monheit G, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320-326.
22. Moy R, Maas C, Monheit G, Huber MB. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11: 77-83.
23. Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J. The efficacy and safety of a new U. S. Botulinum toxin type A in the re-treatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8: 439-444.
24. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebocontrolled study of a new botulinum toxin type A for treatment of glabellar lines: Efficacy and safety. Dermatol Surg 2009; 35: 1893-1901.
25. Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61: 421-425.
26. Galderma SA. Azzalure, Summary of Product Characteristic (SmPC). [WWW document] 2008. URL http://emc. medicines. org. uk/medicine/21985 (last accessed: 4 March 2010).
27. Ipsen Ltd. Dysport, Summary of Product Characteristics (SmPC). [WWW document] 2007 URL http://emc. medicines. org. uk/medicine/870/SPC/Dysport/(last accessed: 4 March 2010).
28. Hexsel D, Rutowitsch MS, de Castro LC, do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of Botulinum toxin Type A reconstituted up to 15 days before injection. Dermatol Surg 2009; 35: 933-939.
29. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223-233.
30. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, doubleblind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 2007; 33: S51-S59. (Pubitemid 46051400)
31. Kane MA, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U. S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: Results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124: 1619-1629.
32. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007; 143: 1447-1449.
33. Farahvash MR, Arad S. Clostridium botulinum type A toxin for the treatment of upper face animation lines: An Iranian experience. J Cosmet Dermatol 2007; 6: 152-158.
34. Dewandre L, Voloshchenko I, Trembach A. Etude comparative pilote de l'efficacité et de la durée d'activité de Dysport vs Botox dans les indications esthétiques classiques (front, glabelle, patte d'oie). J Méd Esth et Chir Derm 2003; 118: 101-107.